Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease

被引:13
|
作者
Bekris, Lynn M. [1 ,2 ]
Millard, Steve [3 ]
Lutz, Franziska [2 ]
Li, Gail
Galasko, Doug R. [5 ,6 ]
Farlow, Martin R. [7 ]
Quinn, Joseph F. [8 ,9 ]
Kaye, Jeffrey A. [8 ,9 ]
Leverenz, James B. [3 ,4 ,10 ]
Tsuang, Debby W. [3 ]
Yu, Chang-En [2 ]
Peskind, Elaine R. [3 ]
机构
[1] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98108 USA
[2] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA
[3] VA Puget Sound Hlth Care Syst, NW Network VISN Mental Illness Res Educ & Clin Ct, Seattle, WA USA
[4] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98108 USA
[5] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA
[6] VA Med Ctr San Diego, San Diego, CA USA
[7] Indiana Univ Sch Med, Dept Neurol, Indianapolis, IN USA
[8] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA
[9] Portland VA Med Ctr, Portland, OR USA
[10] Parkinsons Dis Res Educ & Clin Ctr PADRECC, NW Network VISN 20, Roseburg, OR USA
关键词
FYN; PPP2R4; MAPT; AD; CSF; PROTEIN-TYROSINE KINASE; FYN KINASE; COGNITIVE IMPAIRMENTS; POLYMORPHISMS; ASSOCIATION; BIOMARKERS; DIAGNOSIS; PP2A; CSF;
D O I
10.1002/ajmg.b.32094
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Alzheimer's disease (AD) is characterized by the presence in the brain of amyloid plaques, consisting predominately of the amyloid beta peptide (A beta), and neurofibrillary tangles, consisting primarily of tau. Hyper-phosphorylated-tau (p-tau) contributes to neuronal damage, and both p-tau and total-tau (t-tau) levels are elevated in AD cerebrospinal fluid (CSF) compared to cognitively normal controls. Our hypothesis was that increased ratios of CSF phosphorylated-tau levels relative to total-tau levels correlate with regulatory region genetic variation of kinase or phosphatase genes biologically associated with the phosphorylation status of tau. Eighteen SNPs located within 5' and 3' regions of 5 kinase and 4 phosphatase genes, as well as two SNPs within regulatory regions of the MAPT gene were chosen for this analysis. The study sample consisted of 101 AD patients and 169 cognitively normal controls. Rs7768046 in the FYN kinase gene and rs913275 in the PPP2R4 phosphatase gene were both associated with CSF p-tau and t-tau levels in AD. These SNPs were also differentially associated with either CSF t-tau (rs7768046) or CSF p-tau (rs913275) relative to t-tau levels in AD compared to controls. These results suggest that rs7768046 and rs913275 both influence CSF tau levels in an AD-associated manner. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:874 / 883
页数:10
相关论文
共 50 条
  • [1] Tau oligomers in cerebrospinal fluid in Alzheimer's disease
    Sengupta, Urmi
    Portelius, Erik
    Hansson, Oskar
    Farmer, Kathleen
    Castillo-Carranza, Diana
    Woltjer, Randall
    Zetterberg, Henrik
    Galasko, Douglas
    Blennow, Kaj
    Kayed, Rakez
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2017, 4 (04): : 226 - 235
  • [2] Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease
    Formichi, Patrizia
    Battisti, Carla
    Radi, Elena
    Federico, Antonio
    JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 208 (01) : 39 - 46
  • [3] Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease
    Magnin, Eloi
    Paquet, Claire
    Formaglio, Maite
    Croisile, Bernard
    Chamard, Ludivine
    Miguet-Alfonsi, Carole
    Tio, Gregory
    Dumurgier, Julien
    Roullet-Solignac, Isabelle
    Sauvee, Mathilde
    Thomas-Anterion, Catherine
    Vighetto, Alain
    Hugon, Jacques
    Vandel, Pierre
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 39 (03) : 611 - 616
  • [4] Cerebrospinal fluid levels of Aβ42 and tau:: potential markers of Alzheimer's disease
    Galasko, D
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1998, (53): : 209 - 221
  • [5] GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease
    Cruchaga, Carlos
    Kauwe, John S. K.
    Harari, Oscar
    Jin, Sheng Chih
    Cai, Yefei
    Karch, Celeste M.
    Benitez, Bruno A.
    Jeng, Amanda T.
    Skorupa, Tara
    Carrell, David
    Bertelsen, Sarah
    Bailey, Matthew
    McKean, David
    Shulman, Joshua M.
    De Jager, Philip L.
    Chibnik, Lori
    Bennett, David A.
    Arnold, Steve E.
    Harold, Denise
    Sims, Rebecca
    Gerrish, Amy
    Williams, Julie
    Van Deerlin, Vivianna M.
    Lee, Virginia M. -Y.
    Shaw, Leslie M.
    Trojanowski, John Q.
    Haines, Jonathan L.
    Mayeux, Richard
    Pericak-Vance, Margaret A.
    Farrer, Lindsay A.
    Schellenberg, Gerard D.
    Peskind, Elaine R.
    Galasko, Douglas
    Fagan, Anne M.
    Holtzman, David M.
    Morris, John C.
    Goate, Alison M.
    NEURON, 2013, 78 (02) : 256 - 268
  • [6] Elevated cerebrospinal fluid tau levels: Implications for the early diagnosis of Alzheimer's disease
    Terajima, M
    Arai, H
    Itabashi, S
    Higuchi, M
    Zhu, CQ
    Kosaka, Y
    Nakagawa, T
    Sasaki, H
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1996, 44 (08) : 1012 - 1013
  • [7] Tau, phospho-tau and Ab42 in cerebrospinal fluid in Alzheimer's disease
    Blennow, K
    EUROPEAN PSYCHIATRY, 2002, 17 : 77S - 77S
  • [8] Tau phosphorylation in Alzheimer's disease
    Hanger, D
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S100 - S100
  • [9] Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity
    Samgard, Kaisa
    Zetterberg, Henrik
    Blennow, Kaj
    Hansson, Oskar
    Minthon, Lennart
    Londos, Elisabet
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 25 (04) : 403 - 410
  • [10] Effect of genetic risk factors and disease progression on the cerebrospinal fluid tau levels in Alzheimer's disease
    Arai, H
    Terajima, M
    Miura, M
    Higuchi, S
    Muramatsu, T
    Matsushita, S
    Machida, N
    Nakagawa, T
    Lee, VMY
    Trojanowski, JQ
    Sasaki, H
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1997, 45 (10) : 1228 - 1231